Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06236113 · ClinicalTrials.gov registry record · Phase 4
Low Dose Ketamine for Blunt Thoracic Trauma
A Phase 4 study of Blunt Injury of Thorax and Multiple Rib Fractures, Involving Three Ribs, sponsored by North Memorial Health Care.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06236113: Completed Phase 4 study of Blunt Injury of Thorax and Multiple Rib Fractures, Involving Three Ribs, sponsored by North Memorial Health Care.
NCT06236113 is a Phase 4 study of Blunt Injury of Thorax and Multiple Rib Fractures, Involving Three Ribs that has completed, run by North Memorial Health Care. The registered enrollment target is 50 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06236113, a Phase 4 study of Blunt Injury of Thorax and Multiple Rib Fractures, Involving Three Ribs, has completed, sponsored by North Memorial Health Care.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this Randomized controlled double-blinded trial is to compare the addition of a ketamine infusion to placebo, when added to standard care in adult blunt trauma patients with multiple rib fractures. The main question it aims to answer are: • addition of low dose ketamine infusion (LDKI) decreases narcotic use • does LDKI impact pulmonary complications, readmission, or hospital length of stay Participants will receive usual standard of care with up to 48 hours of LDKI or placebo. If there is a comparison group: Researchers will compare infusion of a saline infusion to LDKI to see if LDKI decreases need for narcotic analgesics use.
Primary Outcome
Standardized method of reporting narcotic analgesic administration by converting opioid narcotics to the equivalent dosage of morphine that would yield same result.
Conditions Studied
Interventions
- DRUG Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution
Study Locations (1)
Minnesota
- North Memorial Health Hospital - Robbinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2023-06-26 |
| Phase | Phase 4 |
What the finished NCT06236113 record still lists
NCT06236113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Blunt Injury of Thorax appearing as the primary indexed condition, and to 1 intervention - of which Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution is the first listed.
NCT06236113 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06236113 about?
NCT06236113 is a clinical study titled "Low Dose Ketamine for Blunt Thoracic Trauma". The goal of this Randomized controlled double-blinded trial is to compare the addition of a ketamine infusion to placebo, when added to standard care in adult blunt trauma patients with multiple rib fractures. The main question it aims to answer are: • addition of low dose ketamine infusion (LDKI) d...
What is the current status of trial NCT06236113?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2021-10-01. Estimated completion is 2023-06-26.
What conditions does trial NCT06236113 study?
This clinical trial studies the following conditions: Blunt Injury of Thorax, Multiple Rib Fractures, Involving Three Ribs.
What interventions are being tested in trial NCT06236113?
The interventions under investigation include: Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution (DRUG).
Who is sponsoring clinical trial NCT06236113?
This trial is sponsored by North Memorial Health Care, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06236113 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06236113's enrollment target sits among peer trials
50 1255th of 2000 higher than 679 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI